Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial-Reference-Cited by-同舟云学术

Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial

Published:2021-12-15 Issue:12 Volume:93 Page:1491-1497
ISSN:2309-5342
Container-title:Terapevticheskii arkhiv
language:
Short-container-title:Terapevticheskii arkhiv

Author:

Arutyunov Gregory P.^ORCID,Lopatin Yuri M.^ORCID,Ametov Aleksandr S.^ORCID,Ageev Fail T.^ORCID,Antsiferov Mikhail B.^ORCID,Villevalde Svetlana V.^ORCID,Vinogradova Nadezhda G.^ORCID,Galstyan Gagik R.^ORCID,Galyavich Albert S.^ORCID,Gilyarevskiy Sergey R.^ORCID,Glezer Maria G.^ORCID,Zhirov Igor V.^ORCID,Ilyin Mikhail V.^ORCID,Lebedeva Anastasiya Iu.^ORCID,Nedogoda Sergey M.^ORCID,Salukhov Vladimir V.^ORCID,Tarlovskaya Ekaterina I.^ORCID,Tereshchenko Sergey N.^ORCID,Fomin Igor V.^ORCID,Khalimov Iurii Sh.^ORCID,Khasanov Niaz R.^ORCID,Cherkashin Dmitriy V.^ORCID,Yakushin Sergey S.^ORCID

Abstract

At an international online expert meeting held on September 16, 2021, the results of the empagliflozin research program EMPA-REG Outcome, EMPEROR-Reduced and EMPEROR-Preserved were reviewed. We analyzed cardiovascular and renal outcomes during the treatment with empagliflozin in patients with chronic heart failure, regardless of the presence of type 2 diabetes mellitus. The positive results of the EMPEROR-Preserved study are updated and their significance for clinical practice is discussed. Several proposals have been adopted that will accelerate the introduction of empagliflozin therapy into practice in patients with heart failure and overcome clinical inertia.

Publisher

Consilium Medicum

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,History,Family Practice

Reference31 articles.

2. CHRONIC HEART FAILURE IN RUSSIAN FEDERATION: WHAT DO WE KNOW AND WHAT TO DO

3. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland

4. Long-Term Trends in the Incidence of and Survival with Heart Failure

5. EURObservationalResearch Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and economic analysis of empagliflozin therapy in patients with heart failure across the ejection fraction range;Russian Journal of Cardiology;2023-07-12

2. Heart failure with preserved left ventricular ejection fraction amidst diabetes mellitus: from general mechanisms to possible therapy tactics;CardioSomatics;2022-12-09

3. Acute decompensation of heart failure: state of the problem;Terapevticheskii arkhiv;2022-10-24

4. Actualization of Positions of Gliflozins in Treatment Algorithms for Patients with Heart Failure: Chronology of Success;I.P. Pavlov Russian Medical Biological Herald;2022-10-07

5. Acute decompensated heart failure. What has changed in the clinical guidelines in 2021?;Consilium Medicum;2022-01-15